ELAN · Elanco Animal Health Inc
$24.90
+0.12 (+0.48%)
At close · Jul 24
Market Cap
$12.44B
Shares
499.45M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$24.78
Open$25.31
Day$24.59–25.54
52W$13.39–27.72
Avg vol 30d4.2M
Short int35.8M · 7.2% float · 8.4d
Short vol27%
Last earningsAug 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 5, 2026
Scheduled
· in 1 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Moderate
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
+4%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
79%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+2%
trailing
YTD return
+10%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
111 of 516 funds reported for Jun 30 · net +116.8K sh shares · +12 new
Insider flow
Accumulating
Net +$199.8K over 90 days · 0% sells
Short interest
Rising
7.17% of float · ▲ +1.7% MoM · 8.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
516 holders — near 3-yr high, broad support
Squeeze score
81
high risk · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
Gross margin
55%
expanding
EPS growth
−169%
Y/Y
Free cash flow
$284.0M
Balance sheet
$3.8B
net debt
Quant / Vol
risk profile
Volatility
44%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
3.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Innovation revenue
· Full Year 2026
Maintained
$1.2B
Revenue
· Full Year 2026
Initiated
$5.01B – $5.09B
prior FY $4.72B
midpoint +7.1% Y/Y
Adjusted EBITDA
· Full Year 2026
Non-GAAP
Maintained
$975M – $1.01B
Adjusted EPS
· Full Year 2026
Non-GAAP
Maintained
$1.03 – $1.09
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
79%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $24 › 200d $23 — 50d above 200d
Institutional flow
Accumulating
111 of 516 funds reported for Jun 30 · net +116.8K sh shares · +12 new
Insider flow
Accumulating
Net +$199.8K over 90 days · 0% sells
Short interest
Rising
7.17% of float · ▲ +1.7% MoM · 8.4 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
516 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $13
Now $25 · 79%
52-wk high $28
vs 200-day avg +6%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $334M | Q1 2026 | — |
|
|
|||
| Adjusted EBITDA Margin non-GAAP | 24.5% | Q1 2026 | — |
|
|
|||
| Net leverage ratio non-GAAP | 3.5 | Q1 2026 | — |
| Innovation revenue | $892M | full year | — |
| Organic constant currency revenue growth | 7% | full year | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELAN
this stock
Elanco Animal Health Inc
|
$12.44B | +9.5% | +6.2% | — | 7.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$55.06B | +10.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.54B | +2.5% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.07B | -4.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELAN | -4.5% | +3.4% | +2.4% | +0.7% | +9.5% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -2.8% | +2.8% | -4.0% | +1.8% | +1.3% |
Key facts
CIK
1739104
CUSIP
28414H103
13F (30d)
113 filings
101 filers
Visit website
Investor relations